Skip to main content

Ariadna Laguna Tuset

I am a neuroscientist with extensive experience in the molecular mechanisms underlying both neurodevelopmental and neurodegenerative diseases of the nervous system. My current research is aimed at identifying new therapeutic targets and biomarkers to improve the diagnosis and treatment of Parkinson's disease.

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Ariadna Laguna Tuset

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am a neuroscientist with extensive experience in the molecular mechanisms underlying both neurodevelopmental and neurodegenerative diseases of the nervous system. My current research is aimed at identifying new therapeutic targets and biomarkers to improve the diagnosis and treatment of Parkinson's disease.

I received my Biology degree, Health and Life Sciences specialization, in 2003 at the Universitat Pompeu Fabra (Barcelona, Spain). I got my Ph.D. in 2008 in the laboratory of Dr. Mariona Arbonés at the Center for Genomic Regulation (CRG, Barcelona, Spain). My Ph.D. was devoted to study the molecular basis of Down Syndrome neurological alterations. In 2009, I joined the group of Professor Thomas Perlmann at the Ludwig Institute for Cancer Research – Karolinska Institutet (Stockholm, Sweden) as a post-doctoral Marie Curie researcher to work on the transcriptional regulation of dopamine neurons during development and in pathological conditions such as Parkinson’s disease.

In 2014, I moved back to Barcelona and joined the Neurodegenerative Diseases Research Group at the Vall d’Hebron Research Institute (VHIR) as a Beatriu de Pinós post-doctoral researcher funded by AGAUR-FP7 Marie Curie Actions. Afterwards, I received a Young Investigator contract from the Spanish government (Ministry of Economy and Competitiveness (MINECO)) and a Junior Leader fellowship from the La Caixa Foundation to establish my own research lines within the group. In addition, I am an associate researcher at the Neuroscience Institute of the Autonomous University of Barcelona (UAB) and Scientific Ambassador of the World Parkinson Coalition.

The research from my team is devoted to elucidate the molecular mechanisms of inter-organ communication in Parkinson’s disease and how this contributes to the pathophysiology and symptoms of this neurodegenerative disorder. Our research contributes to: (i) identify biomarkers for early detection, disease progression or response to treatment, (ii) identify new molecular targets and develop novel therapeutic strategies with disease-modifying potential, (iii) unravel molecular pathways common to other neurodegenerative or metabolic diseases. Researcher ID: F-9561-2016; Orcid: 0000-0002-9732-6677.

Projects

The Gut-Brain axis in Parkinson's disease: novel pathogenic mechanisms and new possibilities for biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: Laia Perez Lasarte
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 74452.89
Reference: 2024 FI-1 00557
Duration: 01/05/2024 - 30/04/2025

El eje cerebro-cuerpo en la enfermedad de Parkinson: de la fisiopatología a los biomarcadores y enfoques terapéuticos.

IP: Ariadna Laguna Tuset
Collaborators: Miriam Izquierdo Sans, Laia Perez Lasarte
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 236350
Reference: RYC2021-032947-I
Duration: 01/01/2023 - 31/12/2027

Ministerio de Ciencia

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Malalties neurodegeneratives , Jordi Riera Heredia, Malalties neurodegeneratives , Helena Xicoy Cortada, Alba Nicolau Vera, Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

Peripheral synucleinopathy: pathogenicity and modulation of propagation

IP: Ariadna Laguna Tuset
Collaborators: -
Funding agency: Parkinson's Foundation
Funding: 54466.62
Reference: PARKINSON.F_IMPACT2022
Duration: 01/07/2022 - 31/07/2025

Related news

The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

Related professionals

Andrea Serrano Mascarós

Andrea Serrano Mascarós

Administration and Management
Clinical Neuroimmunology
Read more
Lluis Martorell Cedres

Lluis Martorell Cedres

Postdoctoral researcher
Transfusional Medicine
Read more
Ma Luisa Navarrete Álvaro

Ma Luisa Navarrete Álvaro

Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Noelia Montoya Clemente

Noelia Montoya Clemente

Research technician
Neurotraumatology and Neurosurgery Research Unit (UNINN)
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.